FilingReader Intelligence
Wantai Biological reports 38% revenue drop, swings to loss
August 20, 2025 at 09:40 AM UTC•By FilingReader AI
Beijing Wantai Biological Pharmacy reported first-half 2025 revenue of 844 million yuan, down 38% year-on-year, with net profit falling 155% to a loss of 144 million yuan.
The company recorded impairment provisions totaling 81 million yuan, including 57 million yuan for credit impairment and 23 million yuan for inventory write-downs.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Wantaibiopharm’s announcement regarding the provision for impairment losses for the first half of 2025August 20, 2025 at 08:00 AM UTC
Wan Tai BioPharm 2025 semi-annual report summaryAugust 20, 2025 at 08:00 AM UTC
Announcement of resolutions from the ninth meeting of the sixth board of directors of Wantai BiologicalAugust 20, 2025 at 08:00 AM UTC
Wantaibio's special report on the deposit and actual use of raised funds for the first half of 2025August 20, 2025 at 08:00 AM UTC
Announcement by Vantai Biological regarding the convening of its 2025 half-year performance briefingAugust 20, 2025 at 08:00 AM UTC
Announcement of resolutions from the ninth meeting of the sixth supervisory board of Vantai Biological.August 20, 2025 at 08:00 AM UTC
SSE:603392•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Beijing Wantai Biological Pharmacy Enterprise publishes news
Free account required • Unsubscribe anytime